• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Australian Journal of Pharmacy >New Pfizer CHC head refutes supermarket support claims
【24h】

New Pfizer CHC head refutes supermarket support claims

机译：辉瑞新的CHC负责人驳斥了超市的支持要求

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

A MID pharmacy concerns that xVphenylephrine-based medicines would soon be available for open sale, new regional director of Pfizer Consumer Healthcare Australia and New Zealand, Sue Hogan, categorically denied to the AJP that the company was behind or would support any such moves. Ms Hogan said a recent review within the National Drugs and Poisons Scheduling Committee (NDPSC) was driven by the trans-Tasman therapeutic review process and was not sponsored by Pfizer. She told the AJP that phenylephrine (PE) 0.5 per cent in liquid or solid had been non-scheduled in Australia since around 1990. Trans-Tasman is simply aligning the descriptions to be less than 50mg per tablet, less than 250mg per box, she said. 'This doesn't reflect on anything we've done. PE was never a market expansion strategy for us. What we've done is focus on PE as a strategy to combat diversion. Ideally, pseudoephedrine would not be behind the counter,' she said.
机译：MID药房担心基于xV苯肾上腺素的药物即将公开发售，澳大利亚辉瑞消费者保健公司和新西兰的新区域总监Sue Hogan向AJP断然否认该公司落后或将支持任何此类举动。霍根女士说，国家禁毒毒理计划委员会（NDPSC）最近进行的审查是由跨塔斯曼病治疗审查程序推动的，而不是由辉瑞公司赞助。她告诉AJP，自1990年左右以来，澳大利亚一直不计划使用0.5％的苯肾上腺素（PE）液体或固体形式。说过。 ”这并不反映我们所做的任何事情。 PE从来都不是我们的市场扩展策略。我们所做的是将PE视为打击转移的策略。理想情况下，伪麻黄碱不会在柜台后面，”她说。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号